Drug Profile
Research programme: cancer therapeutics - Abiogen/University of Texas
Alternative Names: cUV3; Moab-Anti-CD 54; Platinum-Cholic Acid Complex; PT-CLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abiogen Pharma; University of Texas Southwestern Medical Center
- Class Cholic acids; Monoclonal antibodies; Platinum complexes
- Mechanism of Action CD antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma; Multiple myeloma
- Discontinued Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 30 Jul 2010 Preclinical development of the anti-CD54 monoclonal antibody cUV3 is ongoing in Italy for Malignant ocular melanoma and Multiple myeloma